What is the appropriate assessment and management plan for a patient with hypertension, type 2 diabetes mellitus, and chronic kidney disease?

Assessment and Management of Hypertension with Type 2 Diabetes and CKD

Initial Assessment

Measure urine albumin-to-creatinine ratio (UACR) and eGFR immediately, as these two values determine your entire treatment algorithm and medication dosing. 1

• Check serum potassium, creatinine, and calculate eGFR to establish baseline kidney function and identify contraindications 1, 2
• Measure blood pressure using standardized office technique to establish accurate baseline 3
• Assess for volume overload (weight, edema, orthopnea) and review current antihypertensive regimen 1
• Obtain lipid panel, as all patients with diabetes and CKD require statin therapy regardless of baseline LDL 4
• Screen for complications of CKD if eGFR <60: anemia (hemoglobin), metabolic bone disease (calcium, phosphate, PTH), and metabolic acidosis (serum bicarbonate) 1

Blood Pressure Management

Target blood pressure <130/80 mmHg for all patients with diabetes and CKD; consider <120 mmHg systolic in those with severely elevated albuminuria (≥300 mg/g) if tolerated. 1, 3

First-Line: RAS Inhibition

Start an ACE inhibitor or ARB immediately and titrate to the maximum approved tolerated dose—this is the cornerstone of kidney and cardiovascular protection. 1, 4

• If UACR ≥30 mg/g (albuminuria present): ACE inhibitor or ARB is mandatory first-line therapy 1
• Examples: lisinopril 10-40 mg daily, losartan 50-100 mg daily, or telmisartan 40-80 mg daily 4
• The proven benefits in clinical trials were achieved using maximum doses, not submaximal doses 1
• If ACE inhibitor causes intolerable cough, switch to ARB—both provide equivalent renoprotection 3
• Never combine ACE inhibitor + ARB + direct renin inhibitor, as this increases hyperkalemia and acute kidney injury without added benefit 1, 4

Monitoring After RAS Inhibitor Initiation

Check serum creatinine and potassium within 2-4 weeks of starting or increasing the dose of ACE inhibitor or ARB. 1, 4

• Continue therapy unless creatinine rises >30% within 4 weeks—increases ≤30% reflect intended hemodynamic effects, not kidney injury 1, 3
• If creatinine rises >30%: evaluate for acute kidney injury, volume depletion, renal artery stenosis, or nephrotoxic drugs (NSAIDs) 1
• Do not immediately discontinue for hyperkalemia—first attempt medical management: dietary potassium restriction, increase diuretic dose, add sodium bicarbonate if acidotic, or use GI potassium binders 1, 4
• Only reduce or stop ACE inhibitor/ARB if potassium remains >5.5 mmol/L despite these measures or if symptomatic hypotension develops 1, 4

Second-Line: Diuretic Therapy

Add a diuretic promptly when blood pressure remains above target despite maximum-dose RAS inhibition—combination therapy is required in diabetic kidney disease. 4, 3

• If eGFR ≥30 mL/min: use thiazide-like diuretic (chlorthalidone 12.5-25 mg daily preferred over hydrochlorothiazide) 4, 3
• If eGFR <30 mL/min or significant volume overload: use loop diuretic (furosemide 20-40 mg daily), as thiazides lose efficacy at lower GFR 3, 2
• Recheck creatinine, eGFR, and potassium 2-4 weeks after initiating or adjusting diuretic dose 4

Third-Line: Calcium Channel Blocker

If blood pressure remains uncontrolled on ACE inhibitor/ARB plus diuretic, add a dihydropyridine calcium channel blocker (amlodipine 5-10 mg daily or nifedipine extended-release). 4, 3

• This provides additive blood pressure reduction without interfering with RAS blockade 4
• Beta-blockers are an alternative third agent, particularly if high resting heart rate or coronary disease present 3

Diabetes Management

Initiate an SGLT2 inhibitor immediately for all patients with type 2 diabetes and CKD with eGFR ≥20 mL/min/1.73 m²—this provides kidney protection, cardiovascular benefits, and heart failure risk reduction independent of glucose-lowering effects. 1

• Examples: empagliflozin 10 mg daily, dapagliflozin 10 mg daily, or canagliflozin 100 mg daily 1
• Continue SGLT2 inhibitor even as eGFR declines below 20 mL/min/1.73 m², unless kidney replacement therapy is initiated 1
• Withhold temporarily during prolonged fasting, surgery, or critical illness due to ketoacidosis risk 1
• The reversible eGFR dip after SGLT2 inhibitor initiation does not require discontinuation 1

Add metformin if not already prescribed and eGFR ≥30 mL/min/1.73 m²; reduce dose to maximum 1000 mg daily if eGFR 30-45 mL/min/1.73 m²; discontinue if eGFR <30 mL/min/1.73 m². 1, 4

Consider adding a GLP-1 receptor agonist (semaglutide, dulaglutide, or liraglutide) if additional glycemic control needed or to achieve weight loss and cardiovascular protection. 1

Advanced Therapy for Persistent Albuminuria

If UACR remains ≥30 mg/g despite maximum-dose RAS inhibitor and SGLT2 inhibitor, add a nonsteroidal mineralocorticoid receptor antagonist (finerenone 10-20 mg daily) if eGFR >25 mL/min/1.73 m² and potassium is normal. 1

• Finerenone is currently the only nonsteroidal MRA with proven kidney and cardiovascular benefits 1
• Select patients with consistently normal potassium and monitor potassium closely after initiation 1
• This is most appropriate for high-risk patients with persistent albuminuria despite standard therapy 1

Cardiovascular Risk Reduction

Initiate high-intensity statin therapy (atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily) immediately if not already prescribed—all patients with diabetes and CKD require statin therapy regardless of baseline LDL cholesterol. 4, 2

Prescribe aspirin 81 mg daily if clinical atherosclerotic cardiovascular disease is present. 1

Lifestyle Modifications

Restrict dietary sodium to <2 g/day (<5 g salt/day) to enhance effectiveness of RAS blockade and improve blood pressure control. 1, 3, 2

Limit dietary protein intake to 0.8 g/kg/day—avoid high protein intake >1.3 g/kg/day, as this accelerates kidney function decline and increases cardiovascular mortality. 1, 2

Individualize dietary potassium based on serum levels, particularly when using RAS inhibitors or MRAs. 1

Mandate smoking cessation if tobacco use present, as this accelerates CKD progression. 3, 2

Recommend 150 minutes per week of moderate-intensity physical activity. 3

Ongoing Surveillance

Monitor UACR and eGFR annually to detect CKD progression, assess cardiovascular risk, and adjust medication dosing. 1

• If eGFR <60 mL/min/1.73 m²: check serum potassium every 6-12 months (more frequently if on RAS inhibitor or MRA) 1
• Screen for CKD complications every 6-12 months if eGFR 30-60, every 3-5 months if eGFR 15-30, every 1-3 months if eGFR <15 1
• Verify medication dosing is appropriate for current eGFR and minimize nephrotoxin exposure (NSAIDs, iodinated contrast) 1

Common Pitfalls to Avoid

Do not use submaximal doses of ACE inhibitors or ARBs—the renoprotective benefits require maximum tolerated doses. 1, 4

Do not discontinue RAS inhibitors for mild creatinine rises ≤30% or mild hyperkalemia (5.0-5.5 mmol/L)—manage these medically first. 1, 4

Do not rely on ACE inhibitor/ARB monotherapy for blood pressure control—combination therapy with diuretics is almost always required in diabetic CKD. 4

Do not delay SGLT2 inhibitor initiation until glycemic control worsens—the kidney and cardiovascular benefits are independent of glucose lowering. 1